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Abstract
Background: Pertussis continues to challenge medical professionals; recently described increases in incidence may
be due to age-cohort effects, vaccine effectiveness, or changes in testing patterns. Toronto, Canada has recently
experienced increases in pertussis incidence, and provides an ideal jurisdiction for evaluating pertussis
epidemiology due to centralized testing. We evaluated pertussis trends in Toronto using all available specimen
data, which allowed us to control for changing testing patterns and practices.
Methods: Data included all pertussis culture and PCR test records for Greater Toronto from 1993 to 2007. We
estimated incidence trends using Poisson regression models; complex relationships between disease incidence and
test submission were explored with vector autoregressive models.
Results: From 1993 to 2007, 26988 specimens were submitted for testing; 2545 (9.4%) were positive. Pertussis
incidence was 2 per 100,000 from 1993 to 2004 and increased to 10 per 100,000 from 2005-2007, with a
concomitant 6-fold surge in test specimen submissions after the introduction of a new, more sensitive PCR assay.
The relative change in incidence was less marked after adjustment for testing volumes. Bidirectional feedbacks
between test positivity and test submissions were identified.
Conclusions: Toronto’s recent surge in pertussis reflects a true increase in local disease activity; the apparent size
of the outbreak has likely been magnified by increasing use of pertussis testing by clinicians, and by improved test
sensitivity since 2005. These findings may be applicable to changes in pertussis epidemiology that have been
noted elsewhere in North America.
Background
Pertussis is a highly contagious respiratory tract infec-
tion caused by the gram negative bacterium Bordetella
pertussis or less commonly by B. parapertussis [1]. The
disease is classically characterized by three stages [2]: (i)
a nonspecific catarrhal stage; (ii) a subsequent spasmo-
dic stage involves the characteristic paroxysmal cough
with inspiratory whoop,[3] and lasting two to eight
weeks; and (iii) a convalescent phase [3]. The pathogen-
esis of the disease is not fully understood but involves
both direct toxic effects of bacterial endo- and
exotoxins, and also indirect effects of toxins on the host
immune response, including a reduction in lymphocyte
circulation [1,4,5]. While children and adults of any age
may develop pertussis, severe sequelae (including ence-
phalopathy and pneumonia) are most common in
infants aged < 6 months [6-8]. The incidence of pertus-
sis has decreased dramatically in wealthy countries since
the implementation of widespread vaccination programs
(e.g., from ~170/100 000 in the 1930s to fewer than 20/
100 000 in the 1970s in Canada)[9] pertussis is still an
important source of mortality worldwide. The disease
remains one of the leading causes of infant mortality,
[6-8] and causes approximately 300 000 deaths in 50
million cases per year [7,10]. * Correspondence: david.fisman@utoronto.ca
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not occurred despite immunization, and apparent dis-
ease incidence has increased in recent decades [3,6,11].
Recent outbreaks, some with infant deaths, in Notting-
ham and Derby (England) [12], California [13], Ireland
[14] and New South Wales, Australia [15] have been a
source of considerable concern. It has been suggested,
however, that increasingly sensitive PCR methods for
the diagnosis of pertussis may have contributed to
apparent, rather than real, increases in disease incidence
[7,9,16-18]. Other factors invoked to explain pertussis
increases in countries with high rates of immunization
include genetic changes in the pathogen, [19,20] waning
immunity following both vaccination and infection,
[1,3,7] reduced potency of vaccines following the switch
to an acellular vaccine,[21,22] more widespread labora-
tory testing due to increased awareness of the disease in
adults,[22] and lack of immunity or waning immunity in
specific age cohorts [23]. The role played by young ado-
lescents and adults in disease spread,[24] and the recog-
nition of a gradual loss in immunity after natural
infection or vaccination, have led several countries to
advocate booster dosing of pertussis vaccine for young
teens and adults [16,25-27].
Surveillance of pertussis is complicated by differing
manifestations of the disease in infants, adolescents and
adults [28], with the disease presenting as apnea or poor
feeding in infants [2,12], whereas adults and adolescents
often present only with prolonged cough [11], or mini-
mal symptomatology [6]. Nasopharyngeal swab culture
is the historical gold-standard diagnostic modality for
pertussis, but is sensitive only early in the infection,
with a sensitivity < 50% after three weeks of illness or
cough [8]. Serology is even less sensitive but can be
used to diagnose pertussis late in the course of infection
[7]. In recent years, the sensitivity and rapidity of poly-
merase chain reaction (PCR) have brought this testing
modality into widespread use, even if testing is not well-
standardized between laboratories [8,16-18]. The World
Health Organization’s (WHO) most recent guidelines
define a pertussis case as clinically confirmed (without
laboratory confirmation) or laboratory confirmed (and
meeting the clinical case definition)[10]. Prior to 2008,
Canadian case definitions permitted the classification of
ac a s eo fp e r t u s s i sa s“confirmed” based on a positive
laboratory test (including PCR) alone [29,30].
The Greater Toronto Area (GTA) is Canada’sl a r g e s t
metropolitan area. All pertussis testing in the GTA is
performed in only two laboratories (the Public Health
Laboratory–Toronto (PHLT) and the laboratory of the
Hospital for Sick Children (HSC), which share strong
historical linkages, making it possible to evaluate not
only case counts (according to pre-2008 Canadian case
definitions) via laboratory da t a ,b u ta l s ot oe v a l u a t et h e
impact that testing volume and testing practice may
have had on measured disease epidemiology. The region
experienced a documented outbreak of pertussis in
2005-2006 [7,9,16], and experienced a prolonged
increase in pertussis incidence in association with the
introduction of novel testing methodologies. Our objec-
tives were to evaluate changes in pertussis epidemiology
in this large urban setting and to define the relative con-
tributions to disease incidence that may be attributable
to laboratory testing submission volumes, changing test-
ing technologies and underlying disease epidemiology.
Methods
Demographics and Laboratory Characteristics
The Greater Toronto Area (GTA) is the most populous
metropolitan area in Ontario, with a population of
5,113,149 in 2006 over 7,125 km
2[31]. The GTA is
located in the southern part of Ontario and is com-
prised of five administrative regions (Toronto, York,
Halton, Peel and Durham), all of which have separate
public health units charged with disease prevention and
control activities. Pertussis is a notifiable infectious dis-
ease in Ontario and must be reported to regional public
health agencies if compatible with the national case defi-
nition: during the period reported here, a confirmed
case was one with either isolation of B. pertussis or a
positive PCR assay for B. pertussis, regardless of sympto-
matology [29]. Classical symptoms of pertussis (paroxys-
mal cough, post-tussive vomiting or apnea, and
inspiratory whoop) are considered confirmatory in the
absence of laboratory testing of individuals with known
epidemiological links to another confirmed case [29].
Typical case management strategies employed by public
health authorities include evaluation of vaccine status,
with provision of catch-up or booster vaccination as
appropriate, and provision of post-exposure antimicro-
bial therapy to close contacts of cases [32].
GTA pertussis testing is conducted by two labora-
tories: the Public Health Laboratory–Toronto (PHLT)
and the Hospital for Sick Children (HSC). The PHLT
provides primary diagnostic services for hospitals and
healthcare practices in the GTA, as well as confirmatory
testing and reference laboratory services for the entire
province. HSC’s laboratory performs testing principally
on children from the hospital’s inpatient and outpatient
areas, and the hospital’s emergency room. Data included
here cover all pertussis culture and PCR tests conducted
at these two sites from 1993 to 2007. Serological data
are not available. Prior to 1999, only culture isolation of
B. pertussis was available.
Evolution of Testing Procedures
Data on respiratory specimen testing at the PHLT were
available from January 1993 to January 2007. Since
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and PCR on all respiratory specimens submitted for per-
tussis testing, with culture and identification of B. per-
tussis performed as described elsewhere [33]. The PCR
assay introduced at the PHLT in 1999 was a qualitative
a s s a yf o rt h ep r e s e n c eo ft h eI S 4 8 1g e n e ,a ni n s e r t i o n
sequence that appears in multiple copies in the pertussis
genome, and which is not present in several other Bor-
detella species of public health importance (e.g., B.
parapertussis, B. bronchoseptica)[16]. The introduction
of PCR in January 1999 was associated with a change in
specimen collection procedures for pertussis testing,
with the collection media changed from nutrient-rich,
antibiotic impregnated Regan-Lowe medium, to phos-
phate-buffered-saline (PBS) medium. In May 2005, the
PHLT introduced a real-time, quantitative PCR assay
incorporating a fluorescent probe for enhanced assay
sensitivity. Data on respiratory specimens submitted to
the HSC laboratory were available from October 1999
to January 2007; a qualitative IS481-directed PCR was
used on all specimens submitted at HSC during this
time period, and culture was not performed.
Statistical Analysis
Age- and sex-specific population estimates for the Tor-
onto Census Metropolitan Area were obtained from the
1996, 2001, and 2006 Canadian census [31]; data for
inter-census years were estimated through linear inter-
polation and extrapolation. We estimated crude and
adjusted incidence of pertussis testing and disease
occurrence in the Greater Toronto Area using speci-
mens linked by postal code forward sortation area (FSA,
the first three alphanumeric characters of the six charac-
ter Canadian postal code) to the GTA, or which were
identified as having been obtained in one of the five jur-
isdictions comprising the GTA (when FSA was absent).
A small number of test specimens processed by the
HSC laboratory were obtained from individuals with
home FSA outside the GTA. HSC is a major pediatric
tertiary/quaternary care center in Ontario, and conse-
quently provides care to many patients who reside out-
side the GTA. When non-GTA specimens were
obtained from individuals identified as hospital inpati-
ents, these test specimens were included in counts for
the Toronto health region. When non-GTA specimens
processed by HSC were identified as being from outpati-
ents, and when specimens were identified as having
been provided by outside laboratories for reference test-
ing, specimens were excluded from further analysis.
Risk of pertussis by age, gender, season, and time per-
iod were evaluated using census-derived person-time
denominators, with differences in risk evaluated through
calculation of risk differences and 95% confidence limits.
We compared age distributions for cases by time period
(prior to 1999, from 1999 to May 2005, and after May
2005) using the Wilcoxon rank-sum test. Data were
missing for subject gender (5.9%) and age (3.0%). In our
primary analysis, individuals missing values for age were
replaced using random age values drawn from a log-
normal distribution with a mean and standard deviation
identical to that of known ages. Missing gender was
replaced randomly in proportion to known gender dis-
tributions. Sensitivity analyses were also performed, with
records with missing data excluded from analyses.
Specimen factors associated with test positivity, and
with culture or PCR positivity, using categorical meth-
ods, as well as univariable and multivariable logistic
regression models that included age and gender of the
specimen source person, laboratory performing the
tests, and year and season of submission (modeled using
“fast Fourier transforms” ( F F T )[ 3 4 ]t h a tp r o v i d e da n
underlying sinusoidal seasonal baseline).
Temporal trends in pertussis occurrence for the popu-
lation as a whole, and for individual demographic
groups were explored using multivariable Poisson
regression models that included both seasonal smooth-
ers (FFT as described above) and also oscillatory FFT
with 6-year periodicity, to account for the previously
described multi-year periodicity of pertussis [35]. The
assumption of Poisson-distribution of errors was evalu-
ated with the deviance statistic [36] and found to be
appropriate (P = 1.00). The impact of changing testing
procedures on test positivity was evaluated by introdu-
cing step functions at time points where HSC data were
added to the time series, and where test procedures
were modified (i.e., with the introduction of PCR by the
PHLT and HSC laboratories, and with the modification
of PCR testing procedures by the PHLT). Typical time
series models of public health surveillance data are not
able to account for the impact of the volume of test
submission on apparent disease incidence (i.e., lack so-
called “testing denominators”); test submission volumes
in multivariable models were included, to evaluate the
significance of their contribution to model fit using the
log-likelihood test [37]. We performed exploratory ana-
lyses in which we evaluated the differential effects of
test volume on apparent pertussis incidence both by
incorporating multiplicative interaction terms into mod-
els, and by performing restriction analyses in which test-
ing effects were evaluated in models restricted to a
single testing period (i.e., prior to 1999, from January
1999 to April 2005, and from May 2005). We evaluated
differences in testing-adjusted and unadjusted covariates
using the meta-analytic Q-statistic [38], and evaluated
heterogeneity in testing effects by period using the Wald
chi-squared test [38]. Model choice was guided by bal-
ancing model fit against parsimony through minimiza-
tion of Akaike’s information criterion [39].
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submission and test positivity would be complex and
bidirectional, and assessed the relationship between sub-
mission and positivity through construction of vector
autoregressive models, with evidence of causality sought
through the application of Granger’s test [40]. Briefly,
this statistical test (widely applied in econometrics)
seeks to identify cause and effect relationships by com-
paring model prediction when dependent variables and
independent variables (at variable lags) are reversed [40].
Evidence of stationarity of time series using the Dickey-
Fuller unit root test [41] was assessed.
All data analysis was performed with Stata version 11
(StataCorp, College Station, TX). The study was
approved by the Research Ethics Board of the University
of Toronto.
Results
Epidemiological Profile of Pertussis in the Greater
Toronto Area
In total, 26,988 test records were evaluated, of which
2545 (9.4%) tested positive for pertussis. PHLT provided
82.1% of the records and 17.9% came from HSC.
Females accounted for 50.7% of samples and most were
infants, children or adolescents, with 53.4% under 5 and
78.4% under the age of 15 years. There was no clinically
significant change in proportions tested by age or
gender when observations with missing age and gender
classification were excluded from analyses (data not
shown). The average risk of pertussis during the period
under study was 3.68 cases per 100,000 person-years
(95% CI 3.54 to 3.82). The incidence of identified dis-
ease declined sharply with age, and incidence was high-
est in autumn and winter months. The age distribution
of pertussis cases varied significantly across the three
testing periods (P < 0.001 for all two-way comparisons
by Wilcoxon rank-sum test) but there were no consis-
tent patterns observed in changing age composition of
cases over time. Crude pertussis incidence changed
minimally with the introduction of diagnostic PCR in
1999 (risk difference 0 per 100,000, 95% CI -0.01 to
0.02). In contrast, the introduction of a novel, highly
sensitive PCR assay in May 2005 was associated with a
marked increase in pertussis incidence (risk difference
8.09 per 100,000, 95% CI 7.73 to 8.47) (Figure 1 and
Table 1).
In multivariable Poisson models, we identified signifi-
cant seasonal oscillation in incidence, and also signifi-
cant oscillation with 6-year periodicity. Differences in
disease incidence by age group were statistically signifi-
cant in multivariable Poisson models that adjusted for
such temporal trends; in adjusted models, the risk of
pertussis was significantly greater in females than males.
There was no net change in disease incidence after the
Figure 1 Comparative Best-Fit Seasonal Waveforms for Pertussis and Pertussis Testing. Pertussis incidence (thin solid curve), pertussis
culture positivity (dotted curve), and pertussis PCR positivity (dashed curve) all display significant autumn seasonality; testing volumes (dark solid
curve) are also distinctly seasonal but surge in winter.
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marked increase in incidence coincident with the intro-
duction of a highly sensitive pertussis assay in May
2005. Test volume increased sharply after May 2005 as
well; after adjustment for test volume, the relative
increase in pertussis after May 2005 was diminished (P
for heterogeneity < 0.001) though it remained clinically
and statistically significant (Table 2).
The impact of test submission volume on apparent
pertussis incidence was diminished after May 2005 as
opposed to before May 2005 (IRR per 10 specimens
submitted 1.30, 95% CI 1.26 to 1.35 vs. IRR 7.93, 95%
CI 6.80 to 9.26, P for heterogeneity < 0.001). When this
time period was excluded there was no heterogeneity in
the effect of test submissions before as opposed to after
the introduction of PCR in January 1999 (IRR per 10
specimens submitted 9.30, 95% CI 7.74 to 11.18 vs. IRR
4.59, 95% CI 3.35 to 6.27, P = 0.14).
Patterns in Laboratory Testing in the Greater
Toronto Area
Seasonal oscillation in pertussis incidence using fast
Fourier transforms were incorporated into Poisson
models for the time period prior to May 2005. Pertussis
incidence, incidence of culture-confirmed pertussis, inci-
dence of pertussis without culture confirmation, and
Table 1 Crude and Stratum-Specific Rates of Laboratory-Confirmed Pertussis in Greater Toronto Area, 1993-2007
Group Rate per 100,000 Person-Years (95% Confidence Interval)
Overall 3.68 3.54 to 3.82
Age
0-4 31.39 29.79 to 33.08
5-9 9.46 8.60 to 10.40
10-14 7.43 6.68 to 8.26
15-19 2.05 1.67 to 2.51
20+ 0.57 0.51 to 0.64
Gender
Male 3.58 3.39 to 3.79
Female 3.77 3.57 to 3.98
Time Period
Prior to Introduction of PCR (January 1993-December 1998) 2.06 1.89 to 2.24
Initial Introduction of PCR Testing (January 1999-April 2005) 2.06 1.91 to 2.23
Introduction of Highly Sensitive PCR (May 2005-) 10.15 9.64 to 10.70
Table 2 Poisson Regression on Demographic Risks, Temporal Trends, and Testing Effects Associated with Reported
Pertussis Risk in the Greater Toronto Area, Canada
Exclude Testing Volume Include Testing Volume
Variable IRR (95% C.I.) P-value IRR (95% C.I.) P-value
Temporal Trends*
Seasonal Oscillation — 0.04 — < 0.001
Oscillation, 6-year Period — < 0.001 — < 0.001
Demographic Characteristics
Female Gender 1.15 (1.06 to 1.24) < 0.001 1.14 (1.05 to 1.23) < 0.001
Age
0 to 4 years 57.76 (50.91 to 65.53) < 0.001 38.59 (33.84 to 44.00) < 0.001
5 to 9 years 17.16 (14.78 to 19.93) < 0.001 17.34 (14.94 to 20.14) < 0.001
10 to 14 years 13.14 (11.24 to 15.36) < 0.001 14.81 (12.66 to 17.32) < 0.001
15 to 19 years 3.57 (2.82 to 4.52) < 0.001 4.30 (3.40 to 5.44) < 0.001
20 and over 1 (referent) — 1 (referent) —
Testing Practices
Introduction of Novel, Highly Sensitive PCR (May 2005) 3.75 (3.44 to 4.09) < 0.001 2.31 (2.09 to 2.55) < 0.001
Test Submission Volume (per 10 additional test specimens) —— 1.57 (1.53 to 1.61) < 0.001
Pseudo-R
2 0.43 0.47
Akaike’s Information Criterion 11325 10421
NOTE: IRR, incidence rate ratio; CI, confidence interval.
* P-values for oscillation based on sine and cosine terms for oscillation at yearly and 6-yearly intervals.
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nificant annual seasonality (P for oscillation < 0.001 for
all evaluations). However, while test positivity for both
culture- and PCR-positive pertussis displayed autumn
seasonality (peak occurrence weeks 36 to 38), pertussis
testing peaked in winter (week 49) (Figure 1). Heteroge-
neity in phase terms was assessed using the meta-analy-
tic Q-statistic and found significant heterogeneity in
waves (Q-statistic 778.2 on 3 d.f., P < 0.001); however,
the wave forms for seasonality of test-positivity were
homogeneous (Q-statistic 2.4 on 3 d.f., P < 0.31).
Submitted specimen volumes increased over the per-
iod of observation: the increase was gradual prior to
1999 (IRR per year 1.06, 95% CI 1.05 to 1.07), and accel-
erated with the introduction of PCR (IRR 1.11, 95% CI
1.05 to 1.18). There was a sharp increase in test submis-
sion after May 2005 (IRR 2.72, 95% CI 2.61 to 2.83)
(Figure 2). During the period under study, 2545 tests
(9.4%) were positive by either culture or PCR (Figure 3).
Of the positive tests, 63.9% were positive by PCR but
negative by culture, 9.2% were positive by both assays,
and the remaining 26.9% were culture positive without
PCR positivity (most of this latter group had been evalu-
ated at the PHLT prior to the introduction of PCR).
In multivariable logistic regression models constructed
using 1858 specimens positive for pertussis at the PHLT
from 1999 to 2007 (i.e., in a setting where both PCR
and culture were performed in tandem on submitted
specimens), the likelihood of PCR-positive pertussis
without culture confirmation increased over time, and
with the introduction of the novel PCR assay in May
2005, and was elevated in younger age groups, but did
not vary by gender (P = 0.32) or season (P for seasonal
oscillation = 0.06) though the latter was retained in the
model to adjust for residual confounding (Table 3).
We used vector autoregressive models to evaluate the
temporal links between pertussis test positivity and test
submissions. We found strong statistical evidence for
stationarity of both time series for tests (P < 0.001) and
positive tests (P = 0.003). In vector autoregressive mod-
els with 4-week lags test positivity predicted subsequent
test submissions, and test submissions predicted subse-
quent test positivity (Table 4), with strong evidence for
Granger causality over thet i m ep e r i o du n d e rs t u d y .
However, when we restricted our analysis to the period
prior to the introduction of the novel PCR assay (prior
to May 2005), test positivity was found to be Granger
Figure 2 Temporal Trends in Pertussis Testing and Estimated
Crude Pertussis Incidence, Greater Toronto Area, Canada,
1993-2007. Cumulative weekly tests are presented as gray bars;
annualized pertussis rates are presented as rates per million rather
than per 100,000 (as in text) to maintain comparability of scales.
Dashed lines represent initial introduction of PCR testing (January
1999) and introduction of more sensitive PCR assay (May 2005). It
can be seen that there is a strong correlation between specimen
submission and estimated pertussis incidence.
Figure 3 Proportion of Test Submissions Positive by Year.T h e
fraction of tests positive by culture (white bars) has declined over
time, but the fraction positive by PCR (gray bars) has increased
since 2000, with a concomitant rebound in the overall proportion of
test specimens testing positive.
Table 3 Clinical, Temporal and Testing Characteristics
Associated with PCR-Positive, Culture-Negative
Specimens (N = 1858), 1999-2005
Specimen Characteristic Odds
Ratio
95% CI P-value
Age 0-4 2.61 1.71 To 3.98 < 0.001
Age 5-9 1.73 1.02 To 2.93 0.04
Age 10-14 0.41 0.25 To 0.65 < 0.001
Age 15-19 0.41 0.20 To 0.82 0.01
Age > 20 (referent) 1.00 ——— —
Time (years) 1.13 1.03 To 1.25 0.01
Introduction of Novel PCR
(May 2005)
16.35 10.19 To 26.23 < 0.001
NOTE: Model also included sine and cosine terms to adjust for residual
confounding by season (see text). CI, confidence interval.
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Page 6 of 10Table 4 Vector Autoregressive Model Evaluating Prediction of Pertussis Test Positivity by Lagged Pertussis Positivity and Test Submissions
Independent Variable and Lag Entire Study Period (1993-2007) Prior to Novel PCR (1993 to April 2005) Novel PCR (May 2005 to December 2007)
Coefficient (95% CI) P-value Coefficient (95% CI) P-value Coefficient (95% CI) P-value
Test Positivity < 0.001* 0.55* 0.003*
1 week lag 0.49 (0.41 to 0.58) < 0.001 0.20 (0.12 to 0.28) < 0.001 0.56 (0.34 to 0.79) < 0.001
2 week lag 0.42 (0.33 to 0.51) < 0.001 0.22 (0.14 to 0.30) < 0.001 0.55 (0.31 to 0.79) < 0.001
3 week lag 0.16 (0.07 to 0.25) < 0.001 0.18 (0.10 to 0.27) < 0.001 0.10 (-0.14 to 0.34) 0.42
4 week lag -0.22 (-0.31 to -0.14) < 0.001 0.07 (-0.01 to 0.16) 0.07 -0.42 (-0.64 to -0.20) < 0.001
Test Volume
1 week lag 0.02 (0 to 0.04) 0.05 0.01 (-0.01 TO 0.02) 0.52 0.02 (-0.03 to 0.07) 0.41
2 week lag -0.06 (-0.08 to -0.04) < 0.001 -0.02 (-0.04 TO 0.01) 0.08 -0.09 (-0.15 to -0.03) < 0.001
3 week lag 0.03 (0.01 to 0.06) < 0.001 0.01 (-0.01 TO 0.03) 0.48 0.07 (0.01 to 0.13) 0.03
4 week lag 0.01 (0 to 0.03) 0.11 0.00 (-0.01 TO 0.02) 0.68 0.02 (-0.02 to 0.07) 0.27
Test Positivity < 0.001* < 0.001* < 0.001*
1 week lag 1.41 (1.03 to 1.79) < 0.001 0.44 (0.08 TO 0.80) 0.02 1.81 (0.78 to 2.83) < 0.001
2 week lag 0.61 (0.21 to 1.01) < 0.001 0.57 (0.21 TO 0.93) < 0.001 0.94 (-0.15 to 2.02) 0.09
3 week lag -0.05 _0.45 to 0.36) 0.83 0.17 (-0.20 TO 0.53) 0.37 -0.14 (-1.24 to 0.96) 0.81
4 week lag -1.04 (-1.42 to -0.67) < 0.001 -0.20 (-0.56 to 0.16) 0.28 -1.30 (-2.28 to -0.32) 0.01
Test Volume
1 week lag 0.66 (0.58 to 0.74) < 0.001 0.49 (0.41 to 0.57) < 0.001 0.67 (0.45 to 0.90) < 0.001
2 week lag 0.01 (-0.08 to 0.11) 0.77 0.22 (0.13 to 0.31) < 0.001 -0.15 (-0.41 to 0.12) 0.29
3 week lag 0.25 (0.15 to 0.35) < 0.001 0.12 (0.04 to 0.21) 0.01 0.39 (0.12 to 0.66) 0.01
4 week lag -0.08 (-0.16 to 0) 0.04 0.05 (-0.03 to 0.12) 0.26 -0.11 (-0.30 to 0.09) 0.28
NOTE: CI, confidence interval; * signifies P-value from Granger causality test.
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0causal of subsequent test submission, but not vice versa.
During the period from May 2005 to December 2007,
test submission and test positivity were Granger causal
of one another.
Discussion
Despite a greater than 10-fold reduction in the burden
of pertussis-related mortality and morbidity in high- and
middle-income countries with the introduction of
immunization, this disease continues to challenge clini-
cians and public health policymakers [11,42]. These
challenges are rooted in fundamental questions regard-
ing the epidemiology and natural history of pertussis,
and the difficulty encountered by mathematical mode-
lers in building well calibrated simulations for this dis-
ease imply that substantial gaps in knowledge still exist
[43]. We evaluated the epidemiology of pertussis over a
14-year period in a large urban-suburban region of
Ontario, Canada. In the Greater Toronto Area, pertussis
incidence was approximately stable in the early 1990s,
increased somewhat with the introduction of polymerase
chain reaction (PCR) in 1999, and then increased mark-
edly with the introduction of a new, highly sensitive
PCR assay. Because this was a laboratory-derived, popu-
lation-based analysis (due to the fact that all pertussis
testing in the region is performed by the two labora-
tories participating in this study), we had the opportu-
nity to evaluate both changes in disease epidemiology
and changes in testing volumes and test technology, and
to examine the interplay between these two distinct
processes.
We found that the surge in pertussis incidence in the
GTA from 2005 to 2007 likely reflected a combination
of factors, with a true, underlying increase in disease
risk coinciding with the introduction of a highly sensi-
tive assay that probably identified cases that would have
been missed with earlier testing modalities. Surges in
apparent disease incidence with the introduction of
highly sensitive assays for pertussis have been described
in other settings [44], but the process we identify here is
n o ta ss i m p l ea si n c r e a s i n gc a s ec o u n t sa sar e s u l to f
increased test sensitivity. Instead, through the use of
time series analysis, we were able to identify positive
feedback loops, whereby increasing test positivity (due
to either increasing incidence or increased test sensitiv-
ity) led to increased test submissions by clinicians over
subsequent weeks. Such positive feedbacks were pre-
viously noted by us in the context of legionellosis [45]
but to our knowledge this is the first time such feed-
backs have been described for pertussis.
The ability to control for both test volumes and test-
ing technology provides a more nuanced view of the
state of pertussis epidemiology in this jurisdiction than
would be possible using usual surveillance data sources,
which focus on “positive” cases alone, and do not con-
sider frequency of testing. In this instance, adjustment
for test frequency reduced the relative risk of pertussis
in the youngest children, and also diminished the appar-
ent impact of the introduction of a highly sensitive PCR
assay on pertussis incidence. Unfortunately, few jurisdic-
tions have the ability to adjust for testing practices and
volumes when analyzing disease trends, but our findings
show that these factors may be important, particularly
when real or artifactual surges in disease create public
concern, leading to further increases in testing. This is a
concept which has application beyond pertussis; for
example, Vickers and Osgood [46] evaluated an increase
in Chlamydia incidence in the Canadian province of Sas-
katchewan which has centralized testing such that test
volumes are available; in a mathematical model, they
found that changes in test volume alone, rather than
changes in testing characteristics or true underlying
Chlamydia risk, were likely responsible for the surge in
observed Chlamydia incidence in that province. These
authors noted “diminishing returns” from increasing test
submissions, as the marginal identification of cases
declines with expansion of testing. Statistical evidence
for such a phenomenon is seen in our analysis too, in
the diminished (though still statistically significant) asso-
ciation between test submission volumes and estimated
relative risk from May 2005 onwards.
We identified other important changes in the apparent
epidemiology that appear to be driven by testing prac-
tices rather than disease activity per se. For example,
using spectral decomposition, we found that whereas
pertussis in the GTA displays (expected and typical)
autumn seasonality, but pertussis testing displays winter-
time seasonality (perhaps due to the use of pertussis
testing in individuals with undifferentiated cough illness
due to wintertime respiratory viruses). This might be
expected to influence observed seasonal patterns of dis-
ease occurrence, and again confirms the degree to
which a nuanced understanding of disease epidemiology
requires some knowledge of how information on disease
trends is obtained at the level of the microbiology
laboratory.
Like any epidemiological analysis, our analysis is sub-
ject to limitations. Key among these relates to measure-
ment. Although an attempt was made to describe trends
in pertussis in a population with centralized testing, it is
unlikely that all individuals with pertussis underwent
testing, and inasmuch as both likelihood of symptoms
and likelihood of testing depend on age, some of the
effects reported here may relate to differential testing of
different groups. This is a limitation of any population-
based study of pertussis epidemiology. In addition, we
had no access to information on individuals with clinical
pertussis without laboratory testing, though given
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ready availability of laboratory tests, it is unlikely to
have had a major influence on key findings.
Conclusion
In summary, the epidemiology of pertussis in a large
urban-suburban region of Ontario, Canada with centra-
lized pertussis testing over a 15-year period identified
surges in pertussis incidence in this jurisdiction from
2005 onwards. The ability to control for laboratory test
technology and test volume allowed identification of
numerous components to this rise in incidence, includ-
ing improved test sensitivity and a previously unde-
scribed (for pertussis) “positive feedback loop” whereby
increasing reported disease activity appeared to cause
subsequent surges in laboratory test submissions by
clinicians. We were also able to detect distinctive sea-
sonality of pertussis identified by PCR testing without
culture confirmation. In conclusion, the microbiology
laboratory is a key component of smart, integrated dis-
ease surveillance infrastructure; where possible, trend
estimates for pertussis and other communicable diseases
should incorporate data on laboratory test volumes and
technologies, in order to inform smarter and more effi-
cient public health policy.
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